Literature DB >> 10913676

Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization.

C J Breen1, A O'Meara, M McDermott, M Mullarkey, R L Stallings.   

Abstract

Neuroblastoma, the most common extracranial solid tumor of childhood, is associated with a number of genetic abnormalities that are prognostically significant. The most common abnormalities are associated with aggressive clinical behavior and include deletion of distal chromosome 1p, NMYC amplification, and unbalanced gain of the long arm of chromosome 17. There are also other recurrent, but less frequent abnormalities, the clinical significance of which is uncertain. These less common abnormalities include deletion 3p, 11q, and 14q. To gain further clinical insight into some of the less commonly observed abnormalities in neuroblastoma, we performed comparative genomic hybridization (CGH) analysis on 24 primary and metastatic neuroblastomas (6 stage 2, 5 stage 3, 11 stage 4, and 2 stage 4). Nineteen of these tumors were prechemotherapy. A total of 190 abnormalities were detected from these tumors. Four of the 24 tumors studied showed loss of 11q material, with 3 of these tumors also possessing distal chromosome 3p deletions. Our results provide confirmation that deletion of chromosome 3p is nonrandomly associated with deletion of chromosome 11q in neuroblastoma. However, analysis of our results, along with other results reported in the literature, indicate that there is no statistically significant association between 3p and 11q loss and more clinically aggressive tumors.

Entities:  

Mesh:

Year:  2000        PMID: 10913676     DOI: 10.1016/s0165-4608(99)00252-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  21 in total

Review 1.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

2.  Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma.

Authors:  Patrick G Buckley; Leah Alcock; Kenneth Bryan; Isabella Bray; Johannes H Schulte; Alexander Schramm; Angelika Eggert; Pieter Mestdagh; Katleen De Preter; Jo Vandesompele; Frank Speleman; Raymond L Stallings
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

3.  Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

Authors:  John M Maris; George Hii; Craig A Gelfand; Shobha Varde; Peter S White; Eric Rappaport; Saul Surrey; Paolo Fortina
Journal:  Genome Res       Date:  2005-08       Impact factor: 9.043

4.  Neuroblastoma in adolescents: genetic and clinical characterisation.

Authors:  Victoria Castel; Eva Villamón; Adela Cañete; Samuel Navarro; Amparo Ruiz; Carmen Melero; Antonio Herrero; Yania Yáñez; Rosa Noguera
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

5.  Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.

Authors:  Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera
Journal:  Virchows Arch       Date:  2008-06-24       Impact factor: 4.064

6.  Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization.

Authors:  Ben Beheshti; Ilan Braude; Paula Marrano; Paul Thorner; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

Review 7.  MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics.

Authors:  R L Stallings
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11.

Authors:  Katleen De Preter; Jo Vandesompele; Björn Menten; Philippa Carr; Heike Fiegler; Anders Edsjö; Nigel P Carter; Nurten Yigit; Wim Waelput; Nadine Van Roy; Scott Bader; Sven Påhlman; Frank Speleman
Journal:  BMC Genomics       Date:  2005-07-06       Impact factor: 3.969

9.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

10.  Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.

Authors:  Isabella Bray; Kenneth Bryan; Suzanne Prenter; Patrick G Buckley; Niamh H Foley; Derek M Murphy; Leah Alcock; Pieter Mestdagh; Jo Vandesompele; Frank Speleman; Wendy B London; Patrick W McGrady; Desmond G Higgins; Anne O'Meara; Maureen O'Sullivan; Raymond L Stallings
Journal:  PLoS One       Date:  2009-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.